Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2022

View Archived Issues

S2K146 protects against SARS-CoV-2 infection in preclinical models

Exon-skipping antisense oligonucleotides show promise for treating cystic fibrosis

TRAF6 loss linked to development of myeloid malignancies

Discovery of novel mGlu4 receptor PAMs with antipsychotic-like properties

Zealand Pharma divulges LPAM-1 antagonists

Array BioPharma discloses new HER2 inhibitors

Cadila Healthcare synthesizes ENPP2 inhibitors

CGeneTech identifies new CDK inhibitors

Chinese investigators describe AGTR2 antagonists

Repurposed drug promoting systemic arginine catabolism improves energy homeostasis in obese mice

Synergistic antitumor activity of rencofilstat + anti-PD-1 in mice with fatty livers and HCC

IL-2Rbeta agonist MDNA-11 shows promising results in preclinical cancer models

Somatic tissue engineering gives insights into ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...